But let's not ignore some of the positives. Revenue growth 30%, $9m cash, improvements in quality assurance and an exciting medicinal cannabis opportunity as well as other ongoing stream of contracts. At the current market capitalisation I am surprised that the  Cann Group is not more interested in acquiring IDT instead of forking out megabucks building their own manufacturing facility and going through the tedious process of getting regulatory approval as a cGMP manufacturer.
Ann: Appendix 4D - Half Year Report, page-6
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.40M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.0¢ | 11.5¢ | $6.652K | 56.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 118126 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 164944 | 2 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IDT (ASX) Chart |